Wave Life Sciences (WVE) AI Stock Analysis

• Market Cap: $1.44B
• Dividend Yield: N/A
• Average Volume (3M): 2.74M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -14.98%
• EPS Growth: -51.76%
• Country: US
• Employees: 287
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 159,140,460
• 10 Day Avg. Volume: 4,013,294
• 30 Day Avg. Volume: 2,740,143
• PEG Ratio: -0.60
• Price to Book (P/B): 8.16
• Price to Sales (P/S): 15.79
• P/FCF Ratio: -11.26
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 9.44
• Enterprise Value/Gross Profit: 9.90
• Enterprise Value/Ebitda: -6.58
• 1Y Price Target: $20.67
• Price Target Upside: 128.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 49 Neutral
• Price Target: $8.00 ▼(-11.50% Downside)

Wave Life Sciences' overall stock score is primarily impacted by its weak financial performance, with persistent losses and cash flow issues. Despite promising clinical advancements highlighted in the earnings call, the financial challenges weigh heavily on the score. Technical analysis shows moderate bullish momentum, but valuation remains unattractive due to negative earnings. The company's future prospects hinge on successful clinical outcomes and improved financial health.

Positive Factors

Innovative Drug Pipeline

The WVE-007 program for obesity treatment shows potential as a best-in-class therapy, leveraging proprietary technology for enhanced efficacy. This innovation could strengthen Wave's market position in the obesity treatment sector.

Clinical Program Progress

Advancements in clinical programs, such as INHBE for obesity and AATD, indicate potential for future growth and market expansion, enhancing Wave's competitive edge in genetic disorder treatments.

Cash Runway

A strong cash position provides financial stability and flexibility, allowing Wave to sustain operations and invest in R&D without immediate financial pressure.

Negative Factors

Revenue Decline

The decline in revenue reflects challenges in achieving consistent income, which could impact long-term financial health and operational funding.

Increased Net Loss

Rising net losses due to increased R&D and G&A expenses suggest ongoing financial strain, potentially affecting the company's ability to invest in future growth.

Cash Flow Challenges

Persistent cash flow issues indicate difficulties in generating sufficient cash from operations, which could limit Wave's ability to fund its R&D pipeline and other strategic initiatives.

Wave Life Sciences Business Overview & Revenue Model

Company Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

How the Company Makes Money

Wave Life Sciences generates revenue primarily through collaborations and partnerships with pharmaceutical companies, where they receive upfront payments, milestone payments upon achieving specific development targets, and royalties on future sales of partnered products. Additionally, the company may earn revenue from research grants and funding aimed at advancing its proprietary drug development programs. Their strategic collaborations with larger pharmaceutical firms also help mitigate risks and provide essential funding for the development of their drug candidates.

Wave Life Sciences Financial Statement Overview

Summary

Wave Life Sciences is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. The company struggles with negative returns on equity and cash flow issues, despite a high gross profit margin and low leverage.

Income Statement

Wave Life Sciences has faced declining revenues with a negative revenue growth rate of -10.48% in the TTM. The company shows a high gross profit margin of 90.74%, but this is overshadowed by negative net profit and EBIT margins, indicating significant operational challenges. The consistent negative net profit margin suggests ongoing profitability issues.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.16, suggesting manageable leverage. However, the negative return on equity of -78.45% indicates that the company is not generating returns for shareholders. The equity ratio is not explicitly calculated, but the balance sheet shows a moderate level of equity relative to assets.

Cash Flow

Wave Life Sciences has a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth of 10.37% in the TTM. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses, but overall cash flow health remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	93.95M	108.30M	113.31M	3.65M	40.96M	20.08M
Gross Profit	89.59M	108.30M	104.10M	-6.46M	-80.91M	-104.09M
EBITDA	-134.84M	-101.74M	-58.79M	-152.61M	-117.18M	-143.39M
Net Income	-129.87M	-97.01M	-57.51M	-161.82M	-122.25M	-149.91M
Balance Sheet
Total Assets	252.35M	352.21M	274.95M	146.39M	207.01M	279.24M
Cash, Cash Equivalents and Short-Term Investments	208.48M	302.08M	200.35M	88.50M	150.56M	184.50M
Total Debt	21.71M	25.40M	32.12M	37.61M	29.92M	29.30M
Total Liabilities	105.22M	142.69M	235.32M	191.48M	174.51M	196.46M
Stockholders Equity	147.14M	209.51M	39.63M	-45.09M	32.50M	82.78M
Cash Flow
Free Cash Flow	-200.12M	-151.96M	-20.55M	-129.14M	-89.55M	-117.32M
Operating Cash Flow	-199.18M	-151.03M	-19.43M	-127.78M	-88.99M	-115.98M
Investing Cash Flow	-940.00K	-938.00K	-1.11M	-1.25M	-560.00K	-1.34M
Financing Cash Flow	254.57M	253.89M	132.53M	67.19M	55.83M	154.54M

Wave Life Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WVE, the sentiment is Positive. The current price of 9.04 is above the 20-day moving average (MA) of 7.74, above the 50-day MA of 7.78, and above the 200-day MA of 8.24, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 68.87 is Neutral, neither overbought nor oversold. The STOCH value of 56.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WVE.

Wave Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	―	$1.65B	35.55	18.17%	―	1218.82%	―
PGEN	―	$1.21B	―	-668.03%	―	-1.12%	20.77%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WVE	―	$1.44B	-10.13	-171.41%	―	-14.98%	-51.76%
NUVB	―	$1.77B	―	-64.40%	―	900.35%	70.25%
RAPP	―	$1.24B	―	-29.42%	―	―	―
ORIC	―	$1.30B	―	-43.82%	―	―	-7.33%

Wave Life Sciences Corporate Events

Wave Life Sciences Reports Positive INLIGHT Trial Results

On October 29, 2025, Wave Life Sciences announced positive results from its INLIGHT clinical trial of WVE-007 for obesity, showing significant dose-dependent reductions in Activin E levels, which are linked to fat loss. The company also introduced WVE-008, a new RNA editing candidate for liver disease, and highlighted its advancements in RNA editing and silencing technologies, positioning itself as a leader in RNA medicines.

The most recent analyst rating on (WVE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Advances in Duchenne Muscular Dystrophy Study with WVE-N531

Wave Life Sciences Pte. Ltd. is conducting an open-label Phase 1b/2 study titled ‘An Open-label Phase 1b/2 Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical effects of WVE-N531, an antisense oligonucleotide, in patients with Duchenne muscular dystrophy (DMD) who have a specific gene mutation amenable to exon 53 skipping intervention.

Wave Life Sciences’ New Study on WVE-N531: What Investors Need to Know

Wave Life Sciences Pte. Ltd. is conducting an open-label extension study titled ‘An Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, Pharmacokinetics, and Efficacy of WVE-N531 in Patients With Duchenne Muscular Dystrophy Who Participated in Another Study of WVE-N531.’ The study aims to evaluate the long-term safety and effectiveness of the drug WVE-N531 in patients with Duchenne Muscular Dystrophy (DMD) who have previously participated in a related study.

Wave Life Sciences Advances WVE-006 Study for AATD Treatment

Study Overview: Wave Life Sciences Pte. Ltd. is conducting a Phase 1b/2a open-label study titled ‘A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2).’ The study aims to evaluate the safety and effectiveness of WVE-006 in treating alpha-1 antitrypsin deficiency (AATD), a condition that can lead to lung and liver disease.

Wave Life Sciences’ WVE-007 Study: A New Frontier in Obesity Treatment

Wave Life Sciences Pte. Ltd. is conducting a Phase 1 clinical study titled ‘A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living with Overweight or Obesity.’ The study aims to assess the safety and effectiveness of WVE-007, a new treatment for individuals with overweight or obesity, highlighting its potential significance in addressing a prevalent health issue.

Wave Life Sciences Highlights WVE-007 Obesity Treatment

On September 24, 2025, Wave Life Sciences updated its corporate presentation, highlighting advancements in its RNA medicines pipeline, particularly the development of WVE-007 for obesity treatment. The presentation emphasized the potential of WVE-007, a GalNAc-siRNA targeting INHBE, to offer a novel, long-acting, and muscle-sparing approach to obesity, addressing limitations of current treatments like GLP-1s. Preclinical data showed promising results in reducing body weight and visceral fat without muscle loss, suggesting significant implications for the company’s competitive positioning in the RNA therapeutics market.

The most recent analyst rating on (WVE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Announces Positive Results for WVE-006 Study

On September 3, 2025, Wave Life Sciences announced positive results from its ongoing Phase 1b/2a RestorAATion-2 study of WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD). The data demonstrated durable production of serum AAT protein at levels associated with reduced risk of liver and lung diseases, following repeat doses of WVE-006. The study showed that WVE-006 was well tolerated with a favorable safety profile, and the results support a monthly or less frequent dosing regimen. This development represents a significant milestone for RNA editing in treating AATD and highlights the potential of WVE-006 as a transformative treatment option.

The most recent analyst rating on (WVE) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Shareholders Approve Key Proposals

On August 5, 2025, Wave Life Sciences Ltd. held its Annual General Meeting where shareholders approved several key proposals, including an amendment to the 2021 Equity Incentive Plan, increasing authorized shares by 8,000,000. The meeting also saw the re-election of nine directors, the re-appointment of KPMG LLP as the company’s auditor, and approval of compensation plans for non-employee directors and executive officers, reflecting strong shareholder support for the company’s strategic initiatives.

The most recent analyst rating on (WVE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Highlights RNA Platform Advancements

On August 5, 2025, Wave Life Sciences updated its corporate presentation, highlighting advancements in their RNA medicines platform. The presentation emphasized the development of WVE-007, a GalNAc-siRNA targeting INHBE for obesity treatment, which shows promise in reducing weight and visceral fat without muscle loss. This advancement positions Wave Life Sciences as a leader in RNA-based therapies, potentially impacting the treatment landscape for obesity and related metabolic diseases.

The most recent analyst rating on (WVE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges

Wave Life Sciences’ recent earnings call painted a picture of mixed sentiment, with significant advancements in clinical programs juxtaposed against financial challenges. The company reported notable progress in RNA editing and obesity programs, alongside promising results in their Duchenne Muscular Dystrophy (DMD) trials. However, these positive developments were tempered by a decrease in revenue and an increased net loss, highlighting a complex financial landscape.

Wave Life Sciences Advances RNA Medicine Pipeline

Wave Life Sciences Ltd., a clinical-stage biotechnology company, is focused on developing RNA medicines to transform human health, with a diverse pipeline targeting both rare and common disorders. In its latest earnings report for the second quarter of 2025, Wave Life Sciences highlighted significant progress in its clinical trials, particularly in the RestorAATion-2 study for alpha-1 antitrypsin deficiency (AATD) and the INLIGHT trial for obesity.